The APOC3 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the APOC3 gene in human HAP1 cells. This loss-of-function model enables investigation of apolipoprotein C-III (apoC-III) in lipoprotein metabolism. The polyclonal pool offers genetic diversity suitable for population-level functional studies and screening applications without clonal isolation.
HAP1 cells are a near-haploid human cell line with fibroblast-like morphology, derived from KBM-7 chronic myeloid leukemia cells. The near-haploid karyotype simplifies genetic analysis and enhances the efficiency of CRISPR-based functional genomics. These robust cells are amenable to diverse assays, making them an ideal host for knockout studies of lipid metabolism.
APOC3 encodes apoC-III, an inhibitor of lipoprotein lipase (LPL) and hepatic lipase, key enzymes in triglyceride-rich lipoprotein clearance. APOC3 transcription is regulated by PPARA, HNF4A, and FOXA2, and responds to insulin, glucose, and LXR agonists. ApoC-III interacts with APOB, APOE, APOA1, APOC2, LPL, and heparin sulfate proteoglycans to modulate lipolysis and receptor-mediated uptake. Knockout of APOC3 removes this inhibition, leading to increased LPL activity, enhanced hydrolysis of VLDL triglycerides, and improved clearance of remnant lipoproteins via LDLR and LRP1.
In the HAP1 near-haploid background, APOC3 knockout provides a simplified genetic system to dissect triglyceride metabolism. The fibroblast-like cells support studies of lipid uptake, secretion, and intracellular trafficking. Combining APOC3 deletion with HAP1’s manipulability allows precise assessment of apoC-III’s role in VLDL assembly, LPL activity, and hepatic lipase function without polyploid complexity, enabling clean genotype-phenotype correlations.
Applications include functional studies of lipid metabolism, drug target validation for hypertriglyceridemia, and screening for APOC3 modulators. Researchers can use Western blotting, RT-qPCR, LPL activity assays, triglyceride quantification, lipid uptake experiments, and RNA-seq to validate knockout effects. The polyclonal format is suited for high-throughput screens. For further details, contact Ascent Research.
